{"title":"慢性骨髓性白血病:药物耐药性的途径","authors":"C. Corrado","doi":"10.4172/2329-6917.1000E120","DOIUrl":null,"url":null,"abstract":"From 2000 some data relative to IM resistance were available. There are many mechanisms responsible of IM resistance, more often point mutations that cause the progression to blast crisis and death in few months. To circumvent them, more potent TKIs have been subsequently approved [3]. However, another problem arise: these compounds don’t work on all patients because of the different IMresistant mutants of BCR-ABL[4].","PeriodicalId":90223,"journal":{"name":"Journal of leukemia (Los Angeles, Calif.)","volume":" ","pages":"1-2"},"PeriodicalIF":0.0000,"publicationDate":"2017-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Chronic Myelogenous Leukemia: Approaches to Pharmacological Resistance\",\"authors\":\"C. Corrado\",\"doi\":\"10.4172/2329-6917.1000E120\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"From 2000 some data relative to IM resistance were available. There are many mechanisms responsible of IM resistance, more often point mutations that cause the progression to blast crisis and death in few months. To circumvent them, more potent TKIs have been subsequently approved [3]. However, another problem arise: these compounds don’t work on all patients because of the different IMresistant mutants of BCR-ABL[4].\",\"PeriodicalId\":90223,\"journal\":{\"name\":\"Journal of leukemia (Los Angeles, Calif.)\",\"volume\":\" \",\"pages\":\"1-2\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-02-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of leukemia (Los Angeles, Calif.)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4172/2329-6917.1000E120\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of leukemia (Los Angeles, Calif.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2329-6917.1000E120","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Chronic Myelogenous Leukemia: Approaches to Pharmacological Resistance
From 2000 some data relative to IM resistance were available. There are many mechanisms responsible of IM resistance, more often point mutations that cause the progression to blast crisis and death in few months. To circumvent them, more potent TKIs have been subsequently approved [3]. However, another problem arise: these compounds don’t work on all patients because of the different IMresistant mutants of BCR-ABL[4].
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
